KW-2478 is a novel non-ansamycin potent Hsp90 inhibitor with an IC50 of 3.8 nM. KW-2478 is a novel non-purine analogue antagonist for Hsp90. KW-2478 suppressed the binding of bRD to HSP90α in concentration-dependent manner. KW-2478 indicated a potent anti-cancer activity both in vitro and in vivo. KW-2478 clearly prevented cancer cell growth in all cell lines, with EC50 of 101-252, 81.4-91.4 and 120-622 nM for B-cell lymphoma, mantle cell lymphoma and multiple myeloma, respectively. KW-2478 also showd potent growth inhibitory activity in primary CLL (n=3) and NHL (n=2) cells with EC50 of 40-170 nM and 200-400 nM, respectively. KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor. Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression. In NCI-H929 s.c. inoculated model, KW-2478 displayed a significant inhibition of tumor growth and induced the degradation of client proteins in tumors.
|Cell lines||OPM-2/GFP, KMS-11, RPMI 8226, and NCI-H929 cells|
|Preparation method||To measure the IC50, plating OPM-2/green fluorescent protein (GFP) cells, KMS-11 cells, OPM-2/GFP and other cells into 96-well plates and treating them with KW-2478. 72 hours of cultivation later, using Cell Proliferation Reagent WST-1 to determine cell viability . WST reagent is added to the wells, followed by incubation for 4 hours at 37 °C. After that, measuring the absorbance at 450 nm with reference at 650 nm with a microplate spectrophotometer. To examine time dependency of antiproliferative activity of KW-2478, plating the cells into 96-well V-bottomed plates and treating with KW-2478. After 0 hour and at intervals from 3 to 72 hours at 37 °C, the supernatant is aspirated. After drug-free medium is added to the wells, the supernatant is aspirated again. Finally, adding drug-free medium to the wells, and the plates are further incubated for the remainder of the 72-hour period, followed by measurement of cell viabil|
|Concentrations||0.05 - 5 μM|
|Incubation time||3 days|
|Animal models||NCI-H929 tumors s.c. inoculated in SCID mice, OPM-2/GFP i.v. inoculated mouse model|
|Formulation||sterile 0.9% sodium chloride solution|
|Dosages||25, 50 , 100 and 200 mg/kg|
|Administration||Orally administrated once daily for 5 days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO 100 mg/mL|
|Related HSP Products|
Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90).
HM03 is a potent and selective HSPA5 inhibitor with anticancer activity.
Cucurbitacin D induces apoptosis through caspase-3 and phosphorylation of JNK in hepatocellular carcinoma cells.
Arimoclomol maleate (also known as BRX-220) is a heat shock protein amplifier, and is potentially useful for the treatment of Niemann-Pick disease type C (NP-C).
JG-98 is an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.